With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...

Dupilumab is effective for atopic dermatitis, ... “Due to its high cost and multiple indications, tier placement of dupilumab must take many factors into consideration,” they noted.

The most common reason for hospitalization in the combined dupilumab vs. control groups was AD exacerbation, with a 71% risk reduction observed in the dupilumab group (0.7 vs. 2.6 events per 100 ...

If approved, potential barriers to the use of dupilumab in practice include cost and insurance coverage, education and dissemination of study findings, and limited data on side effects, said Narendra.

"Dupilumab will need to be compared with existing treatments for EoE such as dietary management and swallowed topical corticosteroids in terms of efficacy, safety, and quality of life improvements." ...

Additionally, significantly more patients receiving dupilumab versus placebo with or without allergic rhinitis (P=0.008 and P<0.0001) and with or without food allergies (P=0.0002 and P=0.004 ...

Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade. It’s already used to treat different inflammation conditions in the U.S ...

Dupilumab had previously been shown to be effective in the treatment of atopic dermatitis, but this research is the first to examine the drug's efficacy in children with atopic dermatitis and co ...

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Dupilumab was also associated with improvements in lung function (change in pre-bronchodilator FEV 1 from baseline to week 12: 160mL vs 77mL for placebo; P <.0001) that were sustained through 52 ...

Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The blockade by dupilumab of th ...